JGC
GYRE icon

J. Goldman & Co’s Gyre Therapeutics GYRE Stock Holding History

J. Goldman & Co’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,101
Closed -$250K – 383
2021
Q3 		$250K Buy
+8,101
New +$267K 0.01% 309
2020
Q2 		– Sell
-43,468
Closed -$1.43M – 293
2020
Q1 		$1.43M Buy
+43,468
New +$2M 0.17% 123
2018
Q3 		– Sell
-67
Closed -$6K – 316
2018
Q2 		$6K Sell
67
-24,139
-100% -$4.23M ﹤0.01% 342
2018
Q1 		$4.68M Buy
24,206
+7,606
+46% +$1.42M 0.2% 132
2017
Q4 		$1.7M Buy
+16,600
New +$847K 0.09% 203
2013
Q4 		– Sell
-222
Closed -$929K – 256
2013
Q3 		$929K Buy
+222
New +$893K 0.09% 200

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

J. Goldman & Co's GYRE Position: Q4 2021 in Review

J. Goldman & Co sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 8,101 shares — an estimated $250K sold.

J. Goldman & Co first reported a position in GYRE in Q3 2013 and held it in 6 quarters. The position peaked at $4.68M in Q1 2018. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

  • J. Goldman & Co reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • J. Goldman & Co sold 8,101 Gyre Therapeutics shares in Q4 2021, an estimated $250K.
  • J. Goldman & Co first reported a position in Gyre Therapeutics in Q3 2013 and held it in 6 quarters.
  • J. Goldman & Co's Gyre Therapeutics position peaked at $4.68M in Q1 2018.
  • 51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on J. Goldman & Co's 13F filing for Q4 2021, filed 14 Feb 2022.